ALDX sees its 50-day moving average cross bullishly above its 200-day moving average The 50-day moving average for ALDX moved above the 200-day moving average on August 16, 2022. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend. Technical Analysis (Indicators) Bullish Trend Analysis The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected. Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALDX advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are . ALDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. The Aroon Indicator entered an Uptrend today. In of 149 cases where ALDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are . Bearish Trend Analysis The 10-day RSI Indicator for ALDX moved out of overbought territory on August 17, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at . The Momentum Indicator moved below the 0 level on September 06, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on ALDX as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are . The Moving Average Convergence Divergence Histogram (MACD) for ALDX turned negative on August 19, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at . Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are . The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.202) is normal, around the industry mean (26.562). P/E Ratio (0.000) is within average values for comparable stocks, (88.468). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.112). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (309.119). The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents. The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season. The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average. The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents. The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock. ALDX is expected to report earnings to rise 13.43% to -34 cents per share on November 10 The last earnings report on August 05 showed earnings per share of -30 cents, beating the estimate of -31 cents. With 53.84K shares outstanding, the current market capitalization sits at 383.18M. Notable companies The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Global Blood Therapeutics (NASDAQ:GBT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT). Industry description Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry. Market Cap The average market capitalization across the Biotechnology Industry is 1.8B. The market cap for tickers in the group ranges from 160 to 243.34B. NONOF holds the highest valuation in this group at 243.34B. The lowest valued company is CDXI at 160. High and low price notable news The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -9%. MSCLF experienced the highest price growth at 847%, while MOBO experienced the biggest fall at -57%. Volume The average weekly volume growth across all stocks in the Biotechnology Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was -23% Fundamental Analysis Ratings The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows Valuation Rating: 50 A.I.dvisor indicates that over the last year, ALDX has been loosely correlated with CTMX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ALDX jumps, then CTMX could also see price increases. More